Kananji Pharmaceutical Technology (Shanghai) Co., Ltd.

The main purpose is to evaluate the efficacy of CM082 tablets combined with everolimus, compared with everolimus alone or CM082 alone, in patients with metastatic renal cancer who have failed first-line VEGFR-TKI treatment. The safety of CM082 tablets and the safety of CM082 tablets combined with everolimus in the treatment of patients with renal cancer will be further evaluated.

To evaluate the safety, tolerability, pharmacokinetic characteristics and efficacy of intermittent oral administration of CM082 tablets for the treatment of mCNV, and to provide a safe, effective and reasonable dosing regimen for later clinical studies.

To evaluate the safety and tolerability of oral CM082 tablets in the treatment of refractory and relapsed Flt-3-positive acute myeloid leukemia.